Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Ipilimumab

5 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    ECOGMDS1609

    10/19/2017

    DART: Dual Anti-Ctla-4 and Anti-Pd-1 Blockade in Rare Tumors

    Treatment

    VICCTHO1729

    09/14/2017

    A Phase 1/2 Study on the Safety of Rovalpituzumab Tesirine Administered in Combination with Nivolumab or Nivolumab and Ipilimumab for Adults with Extensive- Stage Small Cell Lung Cancer

    Treatment

    VICCMEL16138

    09/08/2017

    A Phase 1/2 Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination with Ipilimumab or Pembrolizumab in Patients with Metastatic Melanoma

    Treatment

    VICCTHO1718

    08/17/2017

    Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CheckMate 816: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 816)

    Treatment

    ECOGTHOS1400

    04/02/2015

    Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer


    Print this page for your doctor